...
机译:基本血小伤症化疗后的治疗性血小板术治疗极端血小板症
Apheresis Unit Department of Hemotherapy and Hemostasis Hematology and Oncology Institute;
Apheresis Unit Department of Hemotherapy and Hemostasis Hematology and Oncology Institute;
Apheresis Unit Department of Hemotherapy and Hemostasis Hematology and Oncology Institute;
Apheresis Unit Department of Hemotherapy and Hemostasis Hematology and Oncology Institute;
Apheresis Unit Department of Hemotherapy and Hemostasis Hematology and Oncology Institute;
Apheresis Unit Department of Hemotherapy and Hemostasis Hematology and Oncology Institute;
essential thrombocytosis; platelets; thrombocytapheresis;
机译:基本血小伤症化疗后的治疗性血小板术治疗极端血小板症
机译:血清肿瘤患者症状血小板减少症的治疗性血小板糖尿病
机译:ASXL1基因的破坏在原发性,实质性血小板增多症和真性红细胞增多症后骨髓纤维化中很常见,但不是必需的血小板增多症或真性红细胞增多症:分子遗传学和临床表型分析血液学
机译:克服胰腺癌的治疗抗性不是PDT和化学疗法的简单组合:在3D肿瘤模型中评估PDT-化学疗法的组合
机译:系统生物学方案下人类血小板增多症的联合遗传和MicroRNA研究。
机译:ASXL1基因的破坏在原发性必需性血小板增多症和真性红细胞增多症后骨髓纤维化中很常见但不是必需性血小板增多症或真性红细胞增多症:分子遗传学和临床表型分析
机译:ASXL1基因的破坏在原发性,实质性血小板增多症和真性红细胞增多症后骨髓纤维化中很常见,但不是必需的血小板增多症或真性红细胞增多症:分子遗传学和临床表型分析
机译:必需的血小板增多症的分子基础